follow us in feedly
MicroCapNewsDaily
  • Mining
  • Cannabis
  • Energy
  • Tech
  • Health
  • Biotech
  • Price Charts

Join Our Community

Facebook

Twitter

RSS

      HomeBiotech

      Biotech

      No Picture
      Biotech

      BioLineRx Class Action Alert: Submit Your Losses to Johnson Fistel

      Jan 5 MicroCapNewsDaily
      The Class Action Seeks to Recover Damages on Shareholders’ Behalf SAN DIEGO, Jan. 05, 2023 (GLOBE NEWSWIRE) — Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf more...
      No Picture
      Biotech

      Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023

      Jan 5 MicroCapNewsDaily
      – Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral Fadraciclib – – 2/3 Partial Responses in Lymphoma and 11/15 Stable Disease in Advanced Solid Tumors – – Expecting more...
      No Picture
      Biotech

      CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event

      Jan 5 MicroCapNewsDaily
      CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event PR Newswire Live video webcast on Wednesday, January 18 th at 10:00 AM ET HOUSTON , January 5, 2023 /PRNewswire/ — CNS more...
      No Picture
      Biotech

      Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

      Jan 5 MicroCapNewsDaily
      LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan more...
      No Picture
      Biotech

      Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate

      Jan 5 MicroCapNewsDaily
      POSH-MAP and PORT-MAP investigator-sponsored trials to evaluate ability of ACER-801 (osanetant) to reduce hot flashes and as neoadjuvant therapy in men with prostate cancer NEWTON, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. more...
      No Picture
      Biotech

      MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

      Jan 5 MicroCapNewsDaily
      Los Angeles, California–(Newsfile Corp. – January 5, 2023) – The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Eiger BioPharmaceuticals, Inc. (“Eiger” or “the Company”) more...
      No Picture
      Biotech

      Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

      Jan 5 MicroCapNewsDaily
      NORCROSS, Ga., Jan. 05, 2023 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced today that in late December 2022, it ended enrollment of NAVIGATE, its seamless, more...
      No Picture
      Biotech

      Arbutus Announces 2023 Corporate Objectives and Provides Financial Update

      Jan 5 MicroCapNewsDaily
      Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into Phase 1 clinical trials in more...
      No Picture
      Biotech

      Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference

      Jan 5 MicroCapNewsDaily
      DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, more...
      No Picture
      Biotech

      EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines

      Jan 5 MicroCapNewsDaily
      – Topline data for Phase 2 DAVIO 2 clinical trial in wet AMD expected in 4Q 2023 – – Enrollment remains on-track in Phase 2 DAVIO 2 clinical trial for wet AMD and Phase 2 more...

      Get Hot Stock Alerts Delivered to Your Inbox

      GET ALERTS
      Privacy

      Biotech

      • BioLineRx Class Action Alert: Submit Your Losses to Johnson Fistel

        Jan 5 MicroCapNewsDaily
        January 5, 2023
        The Class Action Seeks to Recover Damages on Shareholders’ Behalf SAN DIEGO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces t more...
      • Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023

        Jan 5 MicroCapNewsDaily
        January 5, 2023
        – Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral Fadraciclib – – 2/3 Partial Responses in Lymphoma and 11/15 Stable Disease in Advanced Solid Tu more...
      • CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event

        Jan 5 MicroCapNewsDaily
        January 5, 2023
        CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event PR Newswire Live video webcast on more...
      • Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

        Jan 5 MicroCapNewsDaily
        January 5, 2023
        LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical more...
      • Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate

        Jan 5 MicroCapNewsDaily
        January 5, 2023
        POSH-MAP and PORT-MAP investigator-sponsored trials to evaluate ability of ACER-801 (osanetant) to reduce hot flashes and as neoadjuvant therapy in men with prostate cancer NEWTON, Mass., Jan more...
      • MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

        Jan 5 MicroCapNewsDaily
        January 5, 2023
        Los Angeles, California--(Newsfile Corp. - January 5, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Eiger more...
      Advertise With Us
      • Write for Us
      • Submit Press Release
      • Submit Sponsored Post
      Company
      • Authors
      • Contact Us
      Legal
      • Terms of Use
      • Privacy Policy
      • DMCA Policy
      • Disclaimer
      Follow Us

      Copyright © 2023 | 244 Fifth Avenue, Suite N-249 New York, N.Y. 10001 USA | 1-866-773-3540

      Copyright © 2023 | Terms of Use | Privacy Policy | DMCA | Disclaimer | Authors

      244 Fifth Avenue, Suite N-249 New York, N.Y. 10001 USA | 1-866-773-3540